Assignee
IMBRIA PHARMACEUTICALS INC
US·22 granted patents·25 pending applications·89 citations·filing 2017–2025
Top patents by PatentIndex Score
47 records- 0196US11376330B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2020·Granted Jul 5, 2022·13 cites·6 claims
- 0296US10556013B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2018·Granted Feb 11, 2020·27 cites·5 claims
- 0395US11844840B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2022·Granted Dec 19, 2023·3 cites·5 claims
- 0495US10953102B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Mar 23, 2021·15 cites·6 claims
- 0594US10918728B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Feb 16, 2021·14 cites·4 claims
- 0693US11793807B2Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Oct 24, 2023·4 cites·20 claims
- 0792US11883396B2Methods of treating kidney conditions using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2022·Granted Jan 30, 2024·2 cites·20 claims
- 0891US11969422B2Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Apr 30, 2024·3 cites·18 claims
- 0991US11730733B2Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Aug 22, 2023·2 cites·11 claims
- 1086US12318453B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Jun 3, 2025·0 cites·5 claims
- 1186US12076318B2Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Sep 3, 2024·1 cites·18 claims
- 1284US2025262310A1Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1382US12318382B2Methods of treating rheumatic diseases using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Jun 3, 2025·3 cites·11 claims
- 1482US11780811B2Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Oct 10, 2023·1 cites·21 claims
- 1582US11530184B2Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Dec 20, 2022·1 cites·22 claims
- 1681US2026076963A1Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1780US12285428B2Methods of treating kidney conditions using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Apr 29, 2025·0 cites·20 claims
- 1878US12502389B2Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 1978US12233058B2Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Feb 25, 2025·0 cites·9 claims
- 2078US12065410B2Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Aug 20, 2024·0 cites·25 claims
- 2178US11746090B2Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2022·Granted Sep 5, 2023·0 cites·25 claims
- 2277US2025074878A1Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2376US12110275B2Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Oct 8, 2024·0 cites·14 claims
- 2474US2024383857A1Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylateIMBRIA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2572US2024245678A1Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2672US2024374584A1Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2770US2025221986A1Methods of treating kidney conditions using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2867US2019216936A1Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2965US2020352894A1Combination therapyIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3063US10786476B2Combination therapyIMBRIA PHARMACEUTICALS INC·Filed 2017·Granted Sep 29, 2020·0 cites·2 claims
- 3163US2025340523A1Compounds and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3263US2025152581A1Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3360US2026060978A1Methods of treating rheumatic diseases using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3457US2025235447A1Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3555US2024082242A1Combination therapiesIMBRIA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3652US12569480B2Methods of treating fibrosis using compounds that promote glucose oxidationIMBRIA PHARMACEUTICALS INC·Filed 2020·Granted Mar 10, 2026·0 cites·6 claims
- 3752US2021323908A1Process for producing tca cycle intermediate conjugatesIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3851US2022226313A1Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinaseIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3949US2021401833A1Modified release formulations of modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4048US2021401834A1Modified release formulations of modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4148US2023210845A1Dosing methods for treatment of cardiovascular conditionsIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4246US2021346329A1Tca cycle intermediates and methods of use thereofIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4344US2020140375A1Compositions and methods for treating conditions associated with altered tca cycle metabolismIMBRIA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4444US2022249463A1Methods of altering cardiac remodeling using compounds that promote glucose oxidationIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4543US2022168431A1Methods of treating cancer using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4643US2021317072A1H2o crystal forms of a tca cycle intermediate conjugateIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4738US2021346332A1Compositions and methods for treating and preventing leber's hereditary optic neuropathyIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IMBRIA PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →